AC Immune SA (NASDAQ:ACIU) has been assigned an average recommendation of “Buy” from the six brokerages that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $11.00.
A number of analysts have recently issued reports on the stock. ValuEngine raised shares of AC Immune from a “hold” rating to a “buy” rating in a report on Friday, January 3rd. HC Wainwright reissued a “buy” rating and issued a $11.00 price target (up from $8.00) on shares of AC Immune in a research note on Tuesday, December 10th. Zacks Investment Research upgraded shares of AC Immune from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research report on Tuesday. TheStreet upgraded shares of AC Immune from a “d” rating to a “c” rating in a research report on Monday, November 18th. Finally, BidaskClub upgraded shares of AC Immune from a “buy” rating to a “strong-buy” rating in a research report on Friday, January 10th.
A number of large investors have recently bought and sold shares of the stock. Millennium Management LLC boosted its stake in AC Immune by 516.5% during the third quarter. Millennium Management LLC now owns 122,806 shares of the company’s stock worth $607,000 after acquiring an additional 102,887 shares in the last quarter. Tower Research Capital LLC TRC bought a new stake in AC Immune during the third quarter worth about $62,000. Citadel Advisors LLC boosted its stake in AC Immune by 34.2% during the second quarter. Citadel Advisors LLC now owns 166,427 shares of the company’s stock worth $924,000 after acquiring an additional 42,414 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in AC Immune during the second quarter worth about $58,000. Finally, Renaissance Technologies LLC boosted its stake in AC Immune by 12.6% during the second quarter. Renaissance Technologies LLC now owns 248,039 shares of the company’s stock worth $1,377,000 after acquiring an additional 27,789 shares in the last quarter. 27.81% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:ACIU traded down $0.51 during trading hours on Friday, hitting $9.20. The stock had a trading volume of 152,171 shares, compared to its average volume of 214,839. AC Immune has a one year low of $3.25 and a one year high of $11.55. The company has a debt-to-equity ratio of 0.01, a current ratio of 22.08 and a quick ratio of 22.09. The firm has a market capitalization of $665.49 million, a price-to-earnings ratio of -11.22 and a beta of 0.37. The company has a 50 day simple moving average of $8.60 and a two-hundred day simple moving average of $6.30.
AC Immune (NASDAQ:ACIU) last posted its quarterly earnings data on Wednesday, November 13th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.17 by $0.08. AC Immune had a net margin of 45.19% and a return on equity of 19.18%. The company had revenue of $33.90 million during the quarter, compared to the consensus estimate of $31.50 million. Equities research analysts anticipate that AC Immune will post 0.67 earnings per share for the current year.
About AC Immune
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
See Also: Google Finance Portfolio
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.